Skip to content
ppharmaranks
Menu
Abbvie logo

mavik

Pharmaranks rates Mavik 3.6/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Mavik (Trandolapril) is an angiotensin converting enzyme inhibitor used to treat Diabetic Nephropathies, Heart Failure, Hypertension, Left Ventricular Dysfunction.

Trandolapril · by Abbvie

72/100Limited · 1 source

Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate
Verified againstopenFDANIH DailyMedRxClass
~$5.62 /30
Compare online visit pricesWe may earn a commission · never affects ratings
Lower-cost optionsSave up to 86%
This medication~$5.62/30
Cheapest in class · qbrelis~$0.77/30
See FDA-approved alternatives

Key facts

Active ingredient
Trandolapril
Form
Tablet
Strength
Trandolapril 1MG **Federal Register Determination That Product was not Discontinued or Withdrawn for Safety or Effectiveness reasons** · Trandolapril 2MG **Federal Register Determination That Product was not Discontinued or Withdrawn for Safety or Effectiveness reasons** · Trandolapril 4MG **Federal Register Determination That Product was not Discontinued or Withdrawn for Safety or Effectiveness reasons**
Type
Prescription (Rx)
Brand or generic
Brand-name
Manufacturer
Abbvie
What the pharmacy pays
~$5.62 for 30 — not your price
FDA application
NDA020528
Availability
Discontinued (per FDA)

Foods & drinks to be careful with

Well-established interactions for this medicine’s drug class, summarized from public health authorities. General information, not medical advice — always confirm with your pharmacist or the label.

Drug class

May treat (source: NIH RxClass)

See how Mavik ranks — best-rated angiotensin converting enzyme inhibitor for:

Dosage forms

Tablet

The forms currently marketed in the U.S., per the FDA National Drug Code Directory.

Ways to save

Ask for the generic

Same active ingredient, far cheaper. Is there a generic? →

Request a 90-day supply

Bulk fills usually lower the per-dose price vs monthly refills.

Use copay cards

Manufacturer copay cards & patient-assistance programs — especially for brand drugs.

Compare alternatives

A same-class option may cost less. See alternatives →

Frequently asked questions

What does Mavik treat?
Mavik (Trandolapril) may be used to treat diabetic nephropathies, heart failure, hypertension, left ventricular dysfunction, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
How is Mavik rated?
pharmaranks gives Mavik a composite score of 3.6 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
How much does Mavik cost?
Nobody can tell you what you will pay — your price is set by your insurer's formulary, your deductible and the pharmacy's markup, and none of those are published. What IS published is what the pharmacy paid to acquire it: about $5.62 for 30, per the CMS NADAC survey. Treat that as the floor, not the quote — ask the pharmacist for the cash price as well as your copay, because for cheap generics the cash price often wins. Pharmacies pay less for a same-class option, Qbrelis — about $0.77 on the same basis.
Is there a coupon or discount for Mavik?
pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Mavik. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
Who makes Mavik?
Mavik is marketed by Abbvie. You can see Abbvie's full profile, rating, and other products on pharmaranks.
Is Mavik a brand-name or generic drug?
Mavik is a brand-name product with the active ingredient Trandolapril.
Is Mavik available over the counter?
No. Mavik is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
What forms does Mavik come in?
Mavik is currently marketed as tablet, per the FDA's National Drug Code Directory.
What class of drug is Mavik?
Mavik is classified as angiotensin converting enzyme inhibitor, per the FDA's Established Pharmacologic Class.
Is Mavik FDA-registered?
Mavik is on record with the U.S. FDA under application number NDA020528. You can verify this on its official FDA label.
Has Mavik been recalled by the FDA?
Mavik has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
Is Mavik safe?
There's no single safe-or-not verdict. pharmaranks gives Mavik a recall-safety score of 72/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.

Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.

Reviews

No reviews yet. Be the first to write one.

Write a review

Reviews are user opinions, not medical advice. Consult a licensed professional.

People also viewed

Compare Mavik head-to-head

Guides for this medication

Identify a pill by its imprint →Check a drug interaction →Drug recalls →

Browse medications A–Z

Research products from A to Z, compare independent ratings, and find alternatives.